<DOC>
	<DOCNO>NCT02560324</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled crossover study test whether medication call ramelteon ( Brand Name : Remeron ) help smoker quit whether reduces sleep problem smoker experience quit attempt .</brief_summary>
	<brief_title>Effect Ramelteon Smoking Abstinence</brief_title>
	<detailed_description>Ramelteon , FDA-approved treatment insomnia , use treat sleep problem ( e.g. , specifically sleep onset latency ) enhance melatonin receptor function . The investigator propose randomize double-blind placebo-controlled crossover study . Fifty chronic smoker complete validated procedure screen new medication . All subject receive 8mg ramelteon placebo . The order ramelteon placebo receive randomize across participant . This 6-week study consist two 2-week medication phase separate 2-week washout . Each phase include 1 week ad libitum smoking ( baseline ) 1 week medication ( ramelteon vs. placebo ) plus transdermal nicotine patch try abstain smoking ( quit assessment ) . Subjects complete procedure study phase . Following completion study , participant offer standard smoke cessation treatment . For duration study , subject ask keep sleep diary wear armband sleep , provide objective index sleep duration quality ( SensewearPro® armband ) . The primary outcome total number day abstinent ( 5 ) quit assessment period . Intermediate outcome include sleep onset latency ( self-report ) sleep efficiency ( SensewearPro® ) . This study provide information role melatonin system brief abstinence whether enhance melatonin reduces abstinence-induced sleep problem promote smoke relapse . Information obtain study may establish role sleep disturbance promote smoke relapse .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>1 . Smokers 18 65 year age selfreport smoke least 10 cigarette per day least last 6 month . 2 . Interest quit smoke next 2 4 month . 3 . Healthy determine Study Physician , base medical evaluation include medical history physical examination , psychiatric evaluation . 4 . Capable give write informed consent , include compliance requirement restriction list combined consent HIPAA form . 5 . Women childbearing potential must consent use medically accept method birth control participate study ( e.g. , condoms spermicide , oral contraceptive , Depoprovera injection , contraceptive patch , tubal ligation ) . Smoking Behavior : 1 . Current enrollment smoking cessation program , use smoke cessation medication last month plan either next 2 month . 2 . Daily use chew tobacco , snuff and/or snus , electronic cigarette . 3 . Provide carbon monoxide ( CO ) breath sample read less 10 part per million ( ppm ) Intake . Alcohol/Drugs : 1 . Selfreport current alcohol consumption exceed 25 standard drinks/week past 6 month . Subjects tell limit avoid use alcohol study avoid adverse reaction study medication . 2 . Selfreports substance use disorder ( abuse dependence involve alcohol , opiates , cocaine stimulant , benzodiazepine ; nicotine ) last 6 month . 3 . Providing breath alcohol concentration ( BrAC ) read great equal 0.01 session . 4 . A positive urine drug screen cocaine , amphetamine , methamphetamine , benzodiazepine , PCP , methadone , barbiturate , marijuana , ecstasy ( MDMA ) , oxycodone , tricyclic antidepressant , opiate ( low level cutoff 300 ng/mL ) session . Psychiatric Exclusion ( determine selfreport phone screen and/or MINI Intake ) : 1 . Current psychiatric disorder ( depression , bipolar , schizophrenia , hypomanic/manic episode ) determine selfreport and/or MINI psychological interview . 2 . Past history psychiatric disorder ( include suicide attempt ) depression determine selfreport and/or MINI psychological interview . 3 . Suicide risk score MINI great 1 . Medical : 1 . Females currently pregnant , plan pregnancy study , currently breastfeeding/lactating . All female subject shall undergo urine pregnancy test Intake must agree write use approve method contraception . Following enrollment , pregnancy test conduct begin baseline week . 2 . For history jaundice/liver disease : liver function test 20 % outside normal range ; Gammaglutamyl Transpepsidase ( GGT ) value 20 % outside normal range . If Albumin/Globulin ratios 20 % outside normal range abnormal value evaluate clinical significance Study Physician eligibility determine casebycase basis . 3 . Heart/Cardiovascular disease ( e.g. , angina , coronary heart disease , stroke , etc . ) past 6 month . 4 . Endocrine metabolic disorder ( e.g. , TypeI diabetes ) . 5 . Blood disorder ( e.g. , anemia hemophilia ) . 6 . Uncontrolled hypertension ( BP systolic great 159 and/or diastolic great 99 ) * . 7 . Clinically significant dyssomnia ( except insomnia ; e.g . sleep apnea syndrome , narcolepsy ) . Participants present SBP great 159 mmHg and/or DBP great 99 mmHg Intake visit instruct sit quietly 10 minute . Then participant second blood pressure read take 10 minute period . If , second reading SBP great 159 mmHg DBP great 99 mmHg , individual instruct sit comfortably 10 minute third blood pressure reading . If , third reading SBP great 159 mmHg DBP great 99 mmHg , individual ineligible participate . Medication : 1 . Current use recent discontinuation ( within past month ) follow medication : 1 . Antianxiety panic disorder medication ( e.g. , clonazepam , alprazolam ) . 2 . Antipsychotic medication ( e.g. , thorazine , Seroquel ) . 3 . Moodstabilizers ( e.g. , Lithium , Lamictal/lamotrigine , valproic acid , Neurontin/gabapentin , Topamax/topiramate , Tegretol/carbamazepine ) . 4 . Prescription stimulant ( e.g. , Provigil , Ritalin , Adderall ) . 5 . Medications contraindicate ramelteon ( e.g. , fluvoxamine , buprenorphine medication metabolize certain cytochrome P450 enzyme ) 2 . Current use recent discontinuation ( within past 2 week ) follow medication ( subject must agree refrain use sleep aid enrol study ) : 1 . Sleep medication ( e.g. , zolpidem/Ambien , eszopiclone/Lunesta ) 2 . Overthecounter sleep aid ( e.g. , melatonin , diphenhydramine/Benadryl ) 3 . Daily use opiatecontaining medication chronic pain ( Duragesic/fentanyl patch , Percocet , Oxycontin ) . Smokers report take opiatecontaining medication `` asneeded '' basis instruct refrain use study participation test ensure complied requirement . 4 . Known allergy study medication ( e.g. , angioedema ) . Subjects instruct refrain use study prohibit drugs/medications ( recreational prescription ) throughout participation study . After final eligibility confirm , subject report take contraindicate medication ( ) course study period may remain eligible Study Physician and/or Principal Investigator determines contraindicate medication ( ) do/did impact study design , data quality , and/or subject safety/welfare . Subjects permit take necessary prescription medication include within exclusion list study . General Exclusion : 1 . Current , anticipate , pending enrollment another research program next 23 month could potentially affect subject safety and/or study data/design determine Principal Investigator and/or Study Physician . 2 . Not plan live area next two month . 3 . Currently work night shift rotate shift habitual alteration sleep/wake cycle . 4 . Allergy latex adhesive tape . 5 . Inability provide inform consent complete study task determine Principal Investigator . 6 . Not able effectively communicate English ( read , write , speak ) . 7 . Missing 2 dos medication period determine selfreport .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ramelteon</keyword>
	<keyword>Nicotine</keyword>
	<keyword>Nicotine dependence</keyword>
	<keyword>Insomnia</keyword>
	<keyword>Tobacco Dependence</keyword>
</DOC>